enGene Inc. Warrants Stock (NASDAQ:ENGNW)
Previous Close
$0.72
52W Range
$0.57 - $0.74
50D Avg
$0.73
200D Avg
$0.95
Market Cap
$29.13M
Avg Vol (3M)
$6.46K
Beta
-0.39
Div Yield
-
ENGNW Company Profile
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.